Strep Throat Treatment Market Report Scope & Overview:

The Strep Throat Treatment Market was valued at USD 2.34 Billion in 2025 and is expected to reach USD 3.68 Billion by 2035, growing at a CAGR of 4.62% from 2026-2035.

The Strep throat treatment market is gaining popularity owing to the high prevalence of Group A Streptococcus infections among children and teens and continued demand for penicillin and amoxicillin as primary antibiotics used in the treatment. The rapidity of tests for the detection of bacteria is improving diagnoses and increasing the chances of targeted use of antibiotics. The availability of pharmacies offering testing and treatment options is becoming more available across the U.S., the UK and elsewhere. Other options include telemedicine and the online pharmacies. The increased focus on the problems associated with the use of antibiotics is encouraging the search for new treatment methods.

In June 2026, Vaxcyte dosed the first participant in a Phase 1 study of VAX-A1, an investigational vaccine designed to provide broad protection against Group A Streptococcus. The candidate targets conserved antigens linked to immune evasion and could help prevent strep throat and related complications.

Strep Throat Treatment Market Trends

• Rising adoption of pharmacy-based strep test-and-treat services in the U.S. and UK.

• Growing use of rapid molecular point-of-care tests to confirm Group A Strep infection.

• Increasing telemedicine consultations for diagnosis and remote antibiotic prescribing.

• Expanding online pharmacy delivery of antibiotics and symptom-relief products.

• Growing antibiotic stewardship programs to reduce unnecessary sore throat prescriptions.

• Rising clinical development of Group A Streptococcus vaccine candidates.

U.S. Strep Throat Treatment Market Outlook

The U.S. Strep Throat Treatment Market was valued at USD 0.78 Billion in 2025 and is expected to reach USD 1.20 Billion by 2035, growing at a CAGR of 4.36% from 2026-2035.

The U.S. Strep Throat Treatment Market has been rising steadily due to the yearly rise in the number of strep throat infections, especially among school-age children during fall and winter seasons. The coverage for insurance in medical consultations, test kits, and antibiotics is at the same level. There are chain pharmacies and retail clinics that provide testing and treatment services, while urgent care facilities are managing more cases of sore throat. The U.S. has plenty of generic antibiotics, as well as over-the-counter painkillers. Group A Streptococcus activity has raised awareness on the importance of availability of amoxicillin.

In August 2023, Walmart launched a new testing and treatment program in pharmacies across 12 U.S. states, allowing patients with respiratory symptoms to be tested and, if eligible, prescribed medication in one visit. The service operates seven days a week, improving same-day access to strep throat care.

Strep Throat Treatment Market Segment Analysis

• By Disease Type, the Acute Strep Throat segment dominated the Strep Throat Treatment Market with approximately 46.28% share in 2025, while the Tonsillitis segment is the fastest growing with a CAGR of approximately 5.47%.

• By Treatment Type, the Antibiotics segment dominated the Strep Throat Treatment Market with approximately 81.36% share in 2025, while the Pain Relievers segment is the fastest growing with a CAGR of approximately 5.12%.

• By Diagnosis, the Antibody Test segment dominated the Strep Throat Treatment Market with approximately 41.53% share in 2025, while the Throat Culture segment is the fastest growing with a CAGR of approximately 5.36%.

• By Route of Administration, the Oral segment dominated the Strep Throat Treatment Market with approximately 71.84% share in 2025, while the Injectable segment is the fastest growing with a CAGR of approximately 5.68%.

• By End-Use, the Hospitals segment dominated the Strep Throat Treatment Market with approximately 47.26% share in 2025, while the Specialty Clinics segment is the fastest growing with a CAGR of approximately 5.41%.

• By Distribution Channel, the Hospital Pharmacy segment dominated the Strep Throat Treatment Market with approximately 42.17% share in 2025, while the Online Pharmacy segment is the fastest growing with a CAGR of approximately 7.28%.

By Treatment Type, Antibiotics Lead, While Pain Relievers Grow Fastest

Antibiotics segment dominated the Strep Throat Treatment Market in 2025, owing to the fact that antibiotics are prescribed for confirmed Group A Streptococcus infections. Penicillin and amoxicillin remain the drugs of choice due to their efficacy, narrow spectrum, and low cost. People with penicillin allergy are usually administered cephalosporins, macrolides like azithromycin, and clindamycin. Antibiotics reduce the duration of illness, prevent spreading to other people, and help to avoid complications such as rheumatic fever and kidney inflammation. Clinical guidelines of reputable pediatric and infectious disease associations continue to recommend antibiotics, which helps to maintain the segment's dominance in all regions. The availability of generics keeps the prices extremely low.

Pain relievers is the fastest growing segment in the market as people prefer to use supportive therapies to alleviate the symptoms of sore throat pain, fever, and trouble swallowing during the action of antibiotics. OTC products such as acetaminophen, ibuprofen, medicated lozenges, and throat sprays are easily accessible in retail and online pharmacies. The growing self-care practices and availability of these products boost the sales of this segment. Antibiotic stewardship initiatives also encourage physicians to recommend symptom relief for sore throats that tested negative for strep. Healthcare companies continue to develop new products, including fast-acting and kid-friendly formulations, which boosts the sales in this segment.

By Route of Administration, Oral Leads, While Injectable Grows Fastest

Oral Segment held dominance in the Strep Throat Treatment Market during 2025 as most patients are treated with oral antibiotics like penicillin V, amoxicillin, cephalexin, and azithromycin. The oral medicines are easy to administer, do not need any clinical guidance, and are available in tablet, capsule, and flavored liquid suspension form. Their affordability and availability through retail and online pharmacies make them the choice of treatment for most patients. With telemedicine, physicians can diagnose strep throat remotely and prescribe medications directly to pharmacies to be taken by the patients. The liquid form of medication is important for young children.

Injectable segment is the fastest growing route of administration due to the use of intramuscular benzathine penicillin G in patients who cannot complete a full course of oral antibiotics. A single shot of the antibiotic provides effective treatment and is helpful in regions with poor adherence to treatment like rural and poor regions. Injectable antibiotics are also used for severe cases of infection, complications like peritonsillar abscess, and patients who cannot swallow. Preventing rheumatic fever in high burden countries and improved availability of benzathine penicillin will help in driving the growth of the segment. Programs of WHO also aim for increased use of injectable penicillin.

By Distribution Channel, Hospital Pharmacy Leads, While Online Pharmacy Grows Fastest

Hospital pharmacy segment dominated the Strep Throat Treatment Market in 2025, as hospitals manage a large share of severe cases, complications, and patients requiring injectable antibiotics. Hospital pharmacies supply both oral and intravenous treatments for patients admitted with peritonsillar abscess, invasive Group A Strep infections, or other complications. Their bulk purchasing agreements with drug manufacturers and wholesalers allow competitive pricing and reliable supply. Emergency departments also treat many children and adults with sore throats, especially during peak infection seasons. Strong integration with hospital diagnostic laboratories further supports this segment’s leading position across most markets. Hospital formularies also standardize prescribing.

Online pharmacy is the most rapidly growing distribution channel because of consumer inclination towards deliveries and the emergence of telemedicine. Throat soreness with fever may lead patients to want to avoid moving around and hence opt for prescriptions from home and the convenience of next-day delivery. Digital health systems have combined consultations with drug prescription, thus forming a continuous treatment process. The competitive prices in online pharmacies give patients a choice of over-the-counter analgesics and throat medications. Growing regulation of e-pharmacies and internet proliferation in Asia Pacific and Latin America may drive channel development.

Regional Analysis

North America Strep Throat Treatment Market Insights

North America accounted for approximately 38.74% of the Strep Throat Treatment Market in 2025, the largest share among all regions, supported by a high number of annual strep throat cases, strong healthcare access, and broad insurance coverage for diagnosis and treatment. The United States generates most regional revenue, with major pharmacy chains, retail clinics, and urgent care centers offering rapid testing and same-day antibiotic prescriptions. Strong adoption of rapid antigen and molecular point-of-care tests supports accurate diagnosis. A large generic antibiotic market and widely available over-the-counter pain relievers further strengthen regional demand. Rising school outbreaks also increase seasonal treatment volumes across the region.

The contribution from Canada is steady due to the healthcare coverage in the provinces and increasing prescribing of medicines by pharmacists in some provinces. They can diagnose and treat minor illnesses, such as sore throat. Mexico is a developing market due to increasing private healthcare networks and accessibility of antibiotics at retail pharmacies. The use of telemedicine in the region makes the diagnosis and prescribing more convenient for families. Regular outbreaks of Group A Strep infections increase awareness about the necessity of treatment. Periodic shortages of liquid amoxicillin and antibiotic stewardship programs can affect the prescriptions.

Europe Strep Throat Treatment Market Insights

Europe continues to be the second-largest regional market, supported by Germany, the UK, France, Italy, and Spain, where universal healthcare systems provide broad access to diagnosis and treatment. European clinical guidelines generally emphasize careful antibiotic use, with scoring systems such as Centor and FeverPAIN used to decide which patients need antibiotics. Penicillin V remains the preferred first-line treatment in many countries. Strong antibiotic stewardship programs aim to reduce unnecessary prescribing and slow resistance. The rise in Group A Strep infections in recent years has increased public awareness and demand for timely care. Pharmacy services are also expanding steadily across countries.

The UK leads in community pharmacy innovation, with NHS England’s Pharmacy First service allowing pharmacists to assess and treat sore throat using clinical pathways and supply antibiotics when appropriate. Northern Ireland has introduced a similar pharmacy sore throat service. Germany represents a large market due to its high number of physician consultations and strong generic drug industry. France, Italy, and Spain contribute significant demand through primary care and pediatric services. Growing use of rapid strep tests in pharmacies and clinics is expected to improve targeted treatment. However, strict prescribing guidelines may moderate antibiotic volume growth. Pharmacy access continues to improve.

Asia-Pacific Strep Throat Treatment Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Strep Throat Treatment Market, anticipated to record a CAGR of around 5.83% during the forecast period from 2026 to 2035, due to its large pediatric population, improving healthcare access, and rising disposable incomes. China is the largest market in the region, supported by a high volume of pediatric respiratory infections, expanding hospital networks, and strong domestic antibiotic manufacturing. Government health awareness campaigns and improved access to clinics and diagnostic centers are increasing the number of patients receiving timely diagnosis and appropriate antibiotic treatment. Rising disposable incomes are also improving treatment affordability.

India emerges as an important contributor to this growth due to factors like the high number of inhabitants, high rates of throat infection, and efficient manufacture of generic antibiotics by companies such as Sun Pharma, Cipla, Lupin, Aurobindo, and Dr. Reddy’s. Rheumatic heart disease is still a public health problem in some South Asia countries and the Pacific. This adds pressure to provide proper treatment of strep throat in order to prevent its complications. Japan and South Korea enjoy advanced medical services and widespread use of rapid diagnostic tests. There are preventive programs for rheumatic fever in Australia and New Zealand.

MEA & Latin America Strep Throat Treatment Market Insights

The Middle East & Africa region represents a smaller but important share of the Strep Throat Treatment Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, where expanding healthcare infrastructure and insurance coverage support access to treatment. Sub-Saharan Africa carries one of the highest burdens of rheumatic heart disease globally, making effective strep throat treatment an important public health priority. Programs supported by the World Health Organization promote better access to benzathine penicillin and prevention of rheumatic fever. However, limited diagnostic capacity and healthcare access remain challenges in many African countries. Donor programs continue to support improvements.

Latin America is exhibiting sustainable growth. In Latin America, the country that is contributing significantly is Brazil due to its pediatric market, extensive health care coverage, and pharmaceuticals market. Mexico, Argentina, and Colombia are also making contributions through their primary care practices and availability of retail pharmacies. The program to prevent rheumatic fever in various countries utilizes injectable penicillin among at-risk patients. The telemedicine and internet pharmacy usage is becoming prevalent, which is helping urban dwellers gain access. On the other hand, nonprescription antibiotics sold in the open market in certain countries can be attributed to development of resistance. This can cause stricter government policies on future antibiotic sales.

Market Dynamics

Growth Drivers: High Infection Incidence and Expanding Access to Care

Growth in the Strep Throat Treatment Market is primarily attributed to the high global incidence of Group A Streptococcus pharyngitis, which causes millions of sore throat cases each year, especially among children aged five to 15. Strep throat spreads easily in schools, daycare centers, and crowded households, leading to seasonal peaks in fall and winter. Untreated infections can lead to serious complications such as rheumatic fever, rheumatic heart disease, and post-streptococcal glomerulonephritis, making prompt antibiotic treatment essential. Recent increases in Group A Strep activity in several countries have further raised awareness among parents and healthcare providers. School-based outbreaks also drive treatment demand.

Expanding access to diagnosis and treatment is further reinforcing market growth. Rapid antigen detection tests and molecular point-of-care tests allow clinicians and pharmacists to confirm strep throat within minutes, supporting same-day prescribing. Pharmacy-based test-and-treat programs, such as those offered by Walmart in the United States and Pharmacy First in England, are making care more convenient. Telemedicine platforms enable virtual consultations and direct prescription delivery. The wide availability of low-cost generic antibiotics and over-the-counter pain relievers also supports high treatment rates across both developed and emerging markets throughout the forecast period. Growing public health awareness campaigns further encourage people to seek prompt treatment.

Restraints: Antibiotic Resistance and Stewardship Pressure

Increasing antibiotic resistance is another important limiting factor. While Group A Streptococcus is still very sensitive to penicillin, macrolides like azithromycin have shown increased levels of resistance in various parts of the world. This has limited the treatment options for penicillin-allergic patients. Antibiotic abuse in treating viral sore throat is one of the reasons for increased resistance, causing health agencies to have concerns about the problem. Treatment failures and re-infections are possible with the need for repeated consultations and prescriptions. Limited pipeline of novel antibiotics for treating common infections is a limiting factor too, since pharmaceutical companies have no business incentive to develop new medicines.

Antibiotic stewardship programs are another limiting factor, as health organizations are trying to curtail the use of unnecessary prescriptions for sore throats, which are mostly caused by viruses. Clinical scoring systems and diagnostic tests limit the use of antibiotics only to those cases that are proved to be bacterial, thus moderating the number of prescriptions. In addition, low prices of generics such as penicillin and amoxicillin make it difficult for manufacturers to grow revenues from them. Supply shortages of liquid amoxicillin due to periodic infection outbreaks limit its usage and force clinicians to use other medications. In addition, stricter restrictions on over-the-counter sales of antibiotics in some countries may reduce volume in those markets.

Opportunities: Vaccines, Rapid Testing, and Digital Care

The development of Group A Streptococcus vaccines is an important long-term development opportunity since there is no vaccine in the market now. There are vaccine candidates under development like Vaxcyte's VAX-A1, which began Phase 1 trials in 2026, and they should protect against various strep types. The vaccine may be effective in the prevention of strep throat, invasive diseases and even rheumatic heart disease. This will create a new prevention segment. There is also the research related to the development of probiotics and non-antibiotic therapy that opens development opportunities. The investment in prevention and innovation in the treatment of this disease can give companies an advantage in the market of infectious diseases.

The other development opportunity that we see is connected to the increasing popularity of rapid testing and digital care model. The pharmacy test-and-treatment services, retail clinics, and telemedicine services can expand the reach of services and also improve the use of antibiotics appropriately. The over-the-counter or at home strep test will allow people to determine whether they have strep and seek treatment. Online pharmacies and fast delivery of antibiotics and symptom relief drugs become very popular now. The expansion of healthcare infrastructure in Asia Pacific, Latin America and Africa increases the demand for generic antibiotics and prevention of rheumatic fever in these areas.

Recent Developments:

• 2024, NHS England launched its Pharmacy First service, allowing community pharmacists to assess and treat sore throat and supply antibiotics through clinical pathways when appropriate.

• 2023, Northern Ireland introduced a pharmacy sore throat service alongside an extended urinary tract infection service, expanding community pharmacy access to treatment.

Strep Throat Treatment Market Key Players

• Pfizer Inc.

• AstraZeneca plc

• Novartis AG

• GSK plc

• Merck & Co., Inc.

• Sanofi S.A.

• Teva Pharmaceutical Industries Ltd.

• Viatris Inc.

• Sandoz Group AG

• Sun Pharmaceutical Industries Ltd.

• Aurobindo Pharma Limited

• Lupin Limited

• Cipla Limited

• Dr. Reddy’s Laboratories Ltd.

• Abbott Laboratories

• Melinta Therapeutics, LLC

• Bayer AG

• Haleon plc

• Kenvue Inc.

• Hikma Pharmaceuticals PLC

Strep Throat Treatment Market Report Scope: